Sujay Kango - Net Worth and Insider Trading

Sujay Kango Net Worth

The estimated net worth of Sujay Kango is at least $3 Million dollars as of 2024-05-11. Sujay Kango is the EVP, Chief Commercial Officer of Acceleron Pharma Inc and owns about 18,509 shares of Acceleron Pharma Inc (XLRN) stock worth over $3 Million. Sujay Kango is also the Chief Commercial Officer of Infinity Pharmaceuticals Inc and owns about 4,197 shares of Infinity Pharmaceuticals Inc (INFIQ) stock worth over $0. Details can be seen in Sujay Kango's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Sujay Kango has not made any transactions after 2021-09-27 and currently still holds the listed stock(s).

Transaction Summary of Sujay Kango

Sujay Kango Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Sujay Kango owns 3 companies in total, including Acceleron Pharma Inc (XLRN) , Infinity Pharmaceuticals Inc (INFIQ) , and MEI Pharma Inc (MEIP) .

Click here to see the complete history of Sujay Kango’s form 4 insider trades.

Insider Ownership Summary of Sujay Kango

Ticker	Comapny	Transaction Date	Type of Owner
XLRN	Acceleron Pharma Inc	2021-09-27	EVP & Chief Commercial Officer
INFIQ	Infinity Pharmaceuticals Inc	2016-12-13	Chief Commercial Officer
MEIP	MEI Pharma Inc	2023-09-29	director

Sujay Kango Latest Holdings Summary

Sujay Kango currently owns a total of 2 stocks. Among these stocks, Sujay Kango owns 18,509 shares of Acceleron Pharma Inc (XLRN) as of September 27, 2021, with a value of $3 Million and a weighting of 100%. Sujay Kango also owns 4,197 shares of Infinity Pharmaceuticals Inc (INFIQ) as of December 13, 2016, with a value of $0 and a weighting of 0%.

Latest Holdings of Sujay Kango

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XLRN	Acceleron Pharma Inc	2021-09-27	18,509	178.75	3,308,484
INFIQ	Infinity Pharmaceuticals Inc	2016-12-13	4,197	0.00	0

Holding Weightings of Sujay Kango

Sujay Kango Form 4 Trading Tracker

According to the SEC Form 4 filings, Sujay Kango has made a total of 6 transactions in Acceleron Pharma Inc (XLRN) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Acceleron Pharma Inc is the sale of 5,000 shares on September 27, 2021, which brought Sujay Kango around $875,000.

According to the SEC Form 4 filings, Sujay Kango has made a total of 0 transactions in Infinity Pharmaceuticals Inc (INFIQ) over the past 5 years. The most-recent trade in Infinity Pharmaceuticals Inc is the sale of 75,000 shares on December 13, 2016, which brought Sujay Kango around $96,000.

Insider Trading History of Sujay Kango

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Sujay Kango Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Sujay Kango Ownership Network

Ownership Network List of Sujay Kango

No Data

Ownership Network Relation of Sujay Kango

Sujay Kango Owned Company Details

What does Acceleron Pharma Inc do?

Who are the key executives at Acceleron Pharma Inc?

Sujay Kango is the EVP & Chief Commercial Officer of Acceleron Pharma Inc. Other key executives at Acceleron Pharma Inc include SVP & CFO and Treasurer Kevin F Mclaughlin , SVP & General Counsel and Sec. Adam M Veness , and director & CEO and President Habib J Dable .

Acceleron Pharma Inc (XLRN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Acceleron Pharma Inc (XLRN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acceleron Pharma Inc (XLRN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Acceleron Pharma Inc (XLRN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acceleron Pharma Inc Insider Transactions

No Available Data

What does Infinity Pharmaceuticals Inc do?

Who are the key executives at Infinity Pharmaceuticals Inc?

Sujay Kango is the Chief Commercial Officer of Infinity Pharmaceuticals Inc. Other key executives at Infinity Pharmaceuticals Inc include director & President & CEO Adelene Q Perkins , Chief Scientific Officer Stephane Peluso , and Chief Medical Officer Robert Jr. Ilaria .

Infinity Pharmaceuticals Inc (INFIQ) Insider Trades Summary

Over the past 18 months, Sujay Kango made no insider transaction in Infinity Pharmaceuticals Inc (INFIQ). Other recent insider transactions involving Infinity Pharmaceuticals Inc (INFIQ) include a net sale of 410,196 shares made by Adelene Q Perkins ,

In summary, during the past 3 months, insiders sold 0 shares of Infinity Pharmaceuticals Inc (INFIQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 410,196 shares of Infinity Pharmaceuticals Inc (INFIQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 410,196 shares.

Infinity Pharmaceuticals Inc (INFIQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Infinity Pharmaceuticals Inc Insider Transactions

No Available Data

What does MEI Pharma Inc do?

Who are the key executives at MEI Pharma Inc?

Sujay Kango is the director of MEI Pharma Inc. Other key executives at MEI Pharma Inc include Chief Medical Officer Richard G Ghalie , 10 percent owner Amin Nathoo , and 10 percent owner Funicular Funds, Lp .

MEI Pharma Inc (MEIP) Insider Trades Summary

Over the past 18 months, Sujay Kango made no insider transaction in MEI Pharma Inc (MEIP). Other recent insider transactions involving MEI Pharma Inc (MEIP) include a net purchase of 201,660 shares made by Anson Funds Management Lp , a net purchase of 134,440 shares made by Funicular Funds, Lp , and a net purchase of 81,500 shares made by Baltic Charles V. Iii .

In summary, during the past 3 months, insiders sold 0 shares of MEI Pharma Inc (MEIP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MEI Pharma Inc (MEIP) were sold and 340,175 shares were bought by its insiders, resulting in a net purchase of 340,175 shares.

MEI Pharma Inc (MEIP)'s detailed insider trading history can be found in Insider Trading Tracker table.

MEI Pharma Inc Insider Transactions

No Available Data

Sujay Kango Mailing Address

Above is the net worth, insider trading, and ownership report for Sujay Kango. You might contact Sujay Kango via mailing address: 1028 Chambers Court, Bridgewater Nj 08807.

Discussions on Sujay Kango

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.